|
|
|
|
LEADER |
00000cam a2200000Mi 4500 |
001 |
EBOOKCENTRAL_ocn775871780 |
003 |
OCoLC |
005 |
20240329122006.0 |
006 |
m o d |
007 |
cr |n|---||||| |
008 |
120209s2011 gw o 000 0 eng d |
040 |
|
|
|a MHW
|b eng
|e pn
|c MHW
|d EBLCP
|d MERUC
|d OCLCQ
|d DEBSZ
|d OCLCQ
|d ZCU
|d ICG
|d OCLCO
|d OCLCF
|d OCLCQ
|d OCLCO
|d OCLCQ
|d DKC
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCL
|
020 |
|
|
|a 9783527644797
|
020 |
|
|
|a 3527644792
|
029 |
1 |
|
|a AU@
|b 000059852365
|
029 |
1 |
|
|a DEBBG
|b BV044162172
|
029 |
1 |
|
|a DEBSZ
|b 431092745
|
035 |
|
|
|a (OCoLC)775871780
|
050 |
|
4 |
|a QR189 .K889 2011
|
082 |
0 |
4 |
|a 615.3
|
049 |
|
|
|a UAMI
|
100 |
1 |
|
|a Kontermann, Roland.
|
245 |
1 |
0 |
|a Therapeutic Proteins :
|b Strategies to Modulate Their Plasma Half-life.
|
260 |
|
|
|a Weinheim :
|b John Wiley & Sons,
|c 2011.
|
300 |
|
|
|a 1 online resource (374 pages)
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
520 |
|
|
|a For this ready reference, the internationally renowned authority in the field, Roland Kontermann, has assembled a team of outstanding contributors from industry and academia to convey the worldwide knowledge on modifying therapeutic proteins in order to optimize their pharmacological potential. The result is a comprehensive work covering all approaches and aspects of the topic in one handy volume, making this indispensable reading for companies and research institutions working on the development of biopharmaceuticals.
|
505 |
0 |
|
|a Therapeutic Proteins: Strategies to Modulate Their Plasma Half-Lives; Contents; Preface; List of Contributors; Part One: General Information; 1: Half-Life Modulating Strategies -- An Introduction; 1.1 Therapeutic Proteins; 1.2 Renal Clearance and FcRn-Mediated Recycling; 1.3 Strategies to Modulate Plasma Half-Life; 1.3.1 Strategies to Increase the Hydrodynamic Radius; 1.3.2 Strategies Implementing FcRn-Mediated Recycling; 1.4 Half-Life Extension Strategies Applied to a Bispecific Single-Chain Diabody -- A Case Study; 1.5 Conclusion; References.
|
588 |
0 |
|
|a Print version record.
|
590 |
|
|
|a ProQuest Ebook Central
|b Ebook Central Academic Complete
|
650 |
|
0 |
|a Protein drugs
|x Design.
|
650 |
|
0 |
|a Proteins
|x Therapeutic use.
|
650 |
|
6 |
|a Protéines
|x Emploi en thérapeutique.
|
650 |
|
7 |
|a Protein drugs
|x Design
|2 fast
|
650 |
|
7 |
|a Proteins
|x Therapeutic use
|2 fast
|
758 |
|
|
|i has work:
|a Therapeutic proteins (Text)
|1 https://id.oclc.org/worldcat/entity/E39PCFTXHMYWrMKf4RCc7gg3gq
|4 https://id.oclc.org/worldcat/ontology/hasWork
|
776 |
0 |
8 |
|i Print version:
|z 9783527328499
|
856 |
4 |
0 |
|u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=851166
|z Texto completo
|
938 |
|
|
|a EBL - Ebook Library
|b EBLB
|n EBL851166
|
994 |
|
|
|a 92
|b IZTAP
|